Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Current Deferred Tax Assets (2016 - 2017)

Lisata Therapeutics filings provide 6 years of Current Deferred Tax Assets readings, the most recent being $3.5 million for Q1 2017.

  • For the quarter ending Q1 2017, Current Deferred Tax Assets fell 11.23% year-over-year to $3.5 million, compared with a TTM value of $3.5 million through Mar 2017, down 11.23%, and an annual FY2016 reading of $3.6 million, up 23.03% over the prior year.
  • Current Deferred Tax Assets hit $3.5 million in Q1 2017 for Lisata Therapeutics, down from $3.6 million in the prior quarter.
  • The five-year high for Current Deferred Tax Assets was $5.1 million in Q2 2016, with the low at $2.6 million in Q4 2014.
  • Median Current Deferred Tax Assets over the past 4 years was $3.6 million (2016), compared with a mean of $3.6 million.
  • The sharpest move saw Current Deferred Tax Assets soared 73.19% in 2016, then dropped 11.23% in 2017.
  • Year by year, Current Deferred Tax Assets stood at $2.6 million in 2014, then grew by 13.43% to $2.9 million in 2015, then increased by 23.03% to $3.6 million in 2016, then decreased by 1.22% to $3.5 million in 2017.
  • According to Business Quant data, Current Deferred Tax Assets over the past three periods came in at $3.5 million, $3.6 million, and $4.3 million for Q1 2017, Q4 2016, and Q3 2016 respectively.